Suraksha Diagnostic Ltd

Suraksha Diagnostic Ltd has been upgraded from a Hold to a Buy rating, reflecting significant improvements across technical indicators, financial trends, valuation metrics, and overall quality. This upgrade, effective from 1 September 2026, is underpinned by robust quarterly results, a bullish technical outlook, and a favourable valuation compared to peers in the healthcare services sector.

Suraksha Diagnostic Ltd, a micro-cap player in the Healthcare Services sector, has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend. This change is underpinned by a confluence of positive signals from key technical indicators including MACD, Bollinger Bands, and moving averages, signalling renewed investor confidence and potential upside in the near term.

The 50-day moving average has crossed above the 200-day moving average for Suraksha Diagnostic Ltd, signalling a golden cross on 1 Sep 2026. Yet, the broader technical picture is nuanced, with weekly and monthly indicators sending mixed messages amid a backdrop of strong recent price gains.

Suraksha Diagnostic Ltd has surged to a fresh 52-week high of Rs 348.15 on 31 Aug 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of broad technical alignment and sustained gains over the past year, outpacing the Sensex by nearly 19 percentage points.

Suraksha Diagnostic Ltd has surged to a fresh 52-week high of Rs 342.05 on 28 Jun 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals across multiple timeframes, underscoring the stock’s robust upward trajectory despite a broadly cautious market environment.

Suraksha Diagnostic Ltd has surged to a new 52-week high of Rs 335.5 on 26 Aug 2026, marking a significant milestone in its price journey from a low of Rs 224.1 over the past year. This advance comes amid a backdrop of strong technical momentum, with the stock outperforming its healthcare services sector peers and demonstrating robust price action across multiple timeframes.

Suraksha Diagnostic Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating downgraded from Buy to Hold as of 25 August 2026. This revision follows a comprehensive reassessment of the company’s valuation, quality, financial trend, and technical parameters, reflecting a more cautious stance despite robust operational performance and healthy growth metrics.

Suraksha Diagnostic Ltd has seen its investment rating upgraded from Hold to Buy, driven by a combination of improved technical indicators, a more attractive valuation profile, positive financial trends, and solid quality metrics. This upgrade reflects growing investor confidence in the healthcare services company amid a recovering operational performance and favourable market conditions.

Suraksha Diagnostic Ltd has witnessed a significant shift in its valuation parameters, moving from a fair to a very attractive rating. This change comes amid evolving market conditions and peer comparisons within the healthcare services sector, highlighting a compelling opportunity for investors seeking exposure to micro-cap healthcare stocks with solid fundamentals and improving price metrics.

Suraksha Diagnostic Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a marked improvement across financial performance, valuation metrics, and technical indicators. The healthcare services company’s recent quarterly results and evolving market trends have driven this reassessment, signalling cautious optimism for investors amid a micro-cap environment.

Suraksha Diagnostic Ltd, a micro-cap player in the Healthcare Services sector, has exhibited a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This transition is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced market sentiment as the stock edges closer to its 52-week high.

Suraksha Diagnostic Ltd, a micro-cap player in the Healthcare Services sector, has recently exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. This transition is underscored by a complex interplay of technical indicators including MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced market sentiment despite the stock’s modest day gain of 0.44% to ₹308.00 on 17 Aug 2026.

Suraksha Diagnostic Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating. This change reflects a notable improvement in price metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the micro-cap healthcare services company as a compelling option within its sector despite a mixed backdrop of peer valuations and market returns.

Suraksha Diagnostic Ltd, a micro-cap player in the healthcare services sector, has experienced a notable shift in its technical momentum, reflected in a recent upgrade from a Hold to a Sell rating by MarketsMOJO. Despite a robust day gain of 6.22%, the stock’s technical indicators present a complex picture, with some signals pointing to mild bearishness while others remain neutral or sideways, suggesting cautious investor sentiment amid volatile market conditions.

Suraksha Diagnostic Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 August 2026, providing investors with the latest insights into its performance and outlook.